UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss

Clinical cancer research, 2019-02, Vol.25 (3), p.928-936

2019

Volltextzugriff (PDF)

Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

The lancet oncology, 2017-10, Vol.18 (10), p.1360-1372

2017

Volltextzugriff (PDF)

A First in Human Phase 1 Study of CG0070, a GM-CSF Expressing Oncolytic Adenovirus, for the Treatment of Nonmuscle Invasive Bladder Cancer

The Journal of urology, 2012-12, Vol.188 (6), p.2391-2397

2012

Volltextzugriff (PDF)

Phase I Study of DSTP3086S, an Antibody-Drug Conjugate Targeting Six-Transmembrane Epithelial Antigen of Prostate 1, in Metastatic Castration-Resistant Prostate Cancer

Journal of clinical oncology, 2019-12, Vol.37 (36), p.3518-3527

2019

Volltextzugriff (PDF)

Phase I Study of DMOT4039A, an Antibody-Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer

Molecular cancer therapeutics, 2016-03, Vol.15 (3), p.439-447

2016

Volltextzugriff (PDF)

Small-Molecule Antagonists of Myc/Max Dimerization Inhibit Myc-Induced Transformation of Chicken Embryo Fibroblasts

Proceedings of the National Academy of Sciences - PNAS, 2002-03, Vol.99 (6), p.3830-3835

2002

Volltextzugriff (PDF)

Phase 1 study of latozinemab in progranulin‐associated frontotemporal dementia

Alzheimer's & dementia : translational research & clinical interventions, 2024-01, Vol.10 (1), p.e12452-n/a

2024

Volltextzugriff (PDF)

Granulocyte-macrophage colony-stimulating factor (GM-CSF)–secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML)

Blood, 2009-08, Vol.114 (9), p.1736-1745

2009

Volltextzugriff (PDF)

Overall survival (OS) update of the double-blind placebo (PBO)-controlled randomized phase 2 LOTUS trial of first-line ipatasertib (IPAT) + paclitaxel (PAC) for locally advanced/metastatic triple-negative breast cancer (mTNBC)

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.1008-1008

2018

Volltextzugriff (PDF)

Targeting the Siglec-Sialic Acid Immune Axis in Cancer: Current and Future Approaches

Cancer immunology research, 2022-12, Vol.10 (12), p.1423-1432

2022

Volltextzugriff (PDF)

Repeat IV and SC Dosing of the Anti-Sortilin Antibody AL101 (P7-6.007)

Neurology, 2023-04, Vol.100 (17_supplement_2)

2023

Volltextzugriff (PDF)

A First-in-Human Study of the Anti-Sortilin Antibody AL101 (P5-3.003)

Neurology, 2022-05, Vol.98 (18_supplement)

2022

Volltextzugriff (PDF)

A Phase 1 Study of AL003 in Healthy Volunteers and Participants with Alzheimer’s disease (P5-3.002)

Neurology, 2022-05, Vol.98 (18_supplement)

2022

Volltextzugriff (PDF)

AL008 Enhances Myeloid Antitumor Function by Inhibiting SIRPα Signaling and Activating Fc Receptors

The Journal of immunology (1950), 2023-01, Vol.210 (2), p.204-215

2023

Volltextzugriff (PDF)

Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer

Gynecologic oncology, 2020-09, Vol.158 (3), p.631-639

2020

Volltextzugriff (PDF)

ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody-Drug Conjugate Treatment

Clinical cancer research, 2016-04, Vol.22 (7), p.1642-1652

2016

Volltextzugriff (PDF)

Abstract 613: AL009 is a multi-Siglec inhibitor engineered to bind myeloid cells that enhances innate and adaptive immunity to cancer

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.613-613

2022

Volltextzugriff (PDF)

Novel and useful properties of a chimeric plant promoter combining CaMV 35S and MAS elements

Plant molecular biology, 1990-09, Vol.15 (3), p.373-381

1990

Volltextzugriff (PDF)

NGS, RNA-Seq, TIL, and PTEN analyses in prostate cancer specimens from patients enrolled in the study of the Akt inhibitor ipatasertib (Ipat) combined with abiraterone acetate (AA)

Journal of clinical oncology, 2018-02, Vol.36 (6_suppl), p.310-310

2018

Volltextzugriff (PDF)

LOTUS (NCT02162719): A double-blind placebo (PBO)-controlled randomized phase II trial of first-line ipatasertib (IPAT) + paclitaxel (P) for metastatic triple-negative breast cancer (TNBC)

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.1009-1009

2017

Volltextzugriff (PDF)

Abstract CT041: Primary results from FAIRLANE (NCT02301988), a double-blind placebo (PBO)-controlled randomized phase II trial of neoadjuvant ipatasertib (IPAT) + paclitaxel (PAC) for early triple-negative breast cancer (eTNBC)

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.CT041-CT041

2018

Volltextzugriff (PDF)

Mechanisms of and potential treatment strategies for metastatic disease in non-small cell lung cancer

Seminars in thoracic and cardiovascular surgery, 2004, Vol.16 (1), p.40-50

2004

Volltextzugriff (PDF)

Exposure–Response‐Based Product Profile–Driven Clinical Utility Index for Ipatasertib Dose Selection in Prostate Cancer

CPT: pharmacometrics and systems pharmacology, 2019-04, Vol.8 (4), p.240-248

2019

Volltextzugriff (PDF)

Abstract 4310: Predictive biomarkers of tumor sensitivity to STEAP1 antibody-drug conjugate (ADC) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.4310-4310

2015

Volltextzugriff (PDF)

1 – 25 von 45

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(45)
Mit Volltextzugriff
(40)

Publikationsform

Artikel
(45)

Sprache

Englisch
(45)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss

Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

A First in Human Phase 1 Study of CG0070, a GM-CSF Expressing Oncolytic Adenovirus, for the Treatment of Nonmuscle Invasive Bladder Cancer

Phase I Study of DSTP3086S, an Antibody-Drug Conjugate Targeting Six-Transmembrane Epithelial Antigen of Prostate 1, in Metastatic Castration-Resistant Prostate Cancer

Phase I Study of DMOT4039A, an Antibody-Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer

Small-Molecule Antagonists of Myc/Max Dimerization Inhibit Myc-Induced Transformation of Chicken Embryo Fibroblasts

Phase 1 study of latozinemab in progranulin‐associated frontotemporal dementia

Granulocyte-macrophage colony-stimulating factor (GM-CSF)–secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML)

Overall survival (OS) update of the double-blind placebo (PBO)-controlled randomized phase 2 LOTUS trial of first-line ipatasertib (IPAT) + paclitaxel (PAC) for locally advanced/metastatic triple-negative breast cancer (mTNBC)

Targeting the Siglec-Sialic Acid Immune Axis in Cancer: Current and Future Approaches

Repeat IV and SC Dosing of the Anti-Sortilin Antibody AL101 (P7-6.007)

A First-in-Human Study of the Anti-Sortilin Antibody AL101 (P5-3.003)

A Phase 1 Study of AL003 in Healthy Volunteers and Participants with Alzheimer’s disease (P5-3.002)

AL008 Enhances Myeloid Antitumor Function by Inhibiting SIRPα Signaling and Activating Fc Receptors

Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer

Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer

ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody-Drug Conjugate Treatment

Abstract 613: AL009 is a multi-Siglec inhibitor engineered to bind myeloid cells that enhances innate and adaptive immunity to cancer

Novel and useful properties of a chimeric plant promoter combining CaMV 35S and MAS elements

NGS, RNA-Seq, TIL, and PTEN analyses in prostate cancer specimens from patients enrolled in the study of the Akt inhibitor ipatasertib (Ipat) combined with abiraterone acetate (AA)

LOTUS (NCT02162719): A double-blind placebo (PBO)-controlled randomized phase II trial of first-line ipatasertib (IPAT) + paclitaxel (P) for metastatic triple-negative breast cancer (TNBC)

Abstract CT041: Primary results from FAIRLANE (NCT02301988), a double-blind placebo (PBO)-controlled randomized phase II trial of neoadjuvant ipatasertib (IPAT) + paclitaxel (PAC) for early triple-negative breast cancer (eTNBC)

Mechanisms of and potential treatment strategies for metastatic disease in non-small cell lung cancer

Exposure–Response‐Based Product Profile–Driven Clinical Utility Index for Ipatasertib Dose Selection in Prostate Cancer

Abstract 4310: Predictive biomarkers of tumor sensitivity to STEAP1 antibody-drug conjugate (ADC) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Suchergebnisse filtern